R. Zoeller to Cost of Illness
This is a "connection" page, showing publications R. Zoeller has written about Cost of Illness.
Connection Strength
0.481
-
Trasande L, Zoeller RT, Hass U, Kortenkamp A, Grandjean P, Myers JP, DiGangi J, Hunt PM, Rudel R, Sathyanarayana S, Bellanger M, Hauser R, Legler J, Skakkebaek NE, Heindel JJ. Burden of disease and costs of exposure to endocrine disrupting chemicals in the European Union: an updated analysis. Andrology. 2016 07; 4(4):565-72.
Score: 0.118
-
Bellanger M, Demeneix B, Grandjean P, Zoeller RT, Trasande L. Response to the Letter by Middlebeek and Veuger. J Clin Endocrinol Metab. 2015 Jun; 100(6):L54-5.
Score: 0.112
-
Bellanger M, Demeneix B, Grandjean P, Zoeller RT, Trasande L. Neurobehavioral deficits, diseases, and associated costs of exposure to endocrine-disrupting chemicals in the European Union. J Clin Endocrinol Metab. 2015 Apr; 100(4):1256-66.
Score: 0.110
-
Trasande L, Zoeller RT, Hass U, Kortenkamp A, Grandjean P, Myers JP, DiGangi J, Bellanger M, Hauser R, Legler J, Skakkebaek NE, Heindel JJ. Estimating burden and disease costs of exposure to endocrine-disrupting chemicals in the European union. J Clin Endocrinol Metab. 2015 Apr; 100(4):1245-55.
Score: 0.110
-
Attina TM, Hauser R, Sathyanarayana S, Hunt PA, Bourguignon JP, Myers JP, DiGangi J, Zoeller RT, Trasande L. Exposure to endocrine-disrupting chemicals in the USA: a population-based disease burden and cost analysis. Lancet Diabetes Endocrinol. 2016 12; 4(12):996-1003.
Score: 0.031